Valuation: Polaris Group

Market Cap 928.68Cr 29Cr 25Cr 24Cr 21Cr 40Cr 2.78TCr 41Cr 276.02Cr 107.92Cr 1.39TCr 108.97Cr 106.61Cr 4.62TCr P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 980.37Cr 31Cr 26Cr 25Cr 23Cr 43Cr 2.93TCr 43Cr 291.38Cr 113.93Cr 1.47TCr 115.04Cr 112.54Cr 4.88TCr EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.37%
1 week-2.70%
Current month-0.46%
1 month-15.62%
3 months-36.09%
6 months-63.88%
Current year-65.27%
1 week 10.8
Extreme 10.8
11.25
1 month 10.8
Extreme 10.8
12.65
Current year 10.8
Extreme 10.8
35.95
1 year 10.8
Extreme 10.8
44.55
3 years 10.8
Extreme 10.8
88.1
5 years 10.8
Extreme 10.8
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.37%-2.70%-69.45%-86.86% 29Cr
+0.68%-2.28%+1.91%+19.70% 4.84TCr
+3.89%+1.96%+478.96%+620.48% 4.37TCr
+3.45%+0.13%+12.57%+86.95% 3.95TCr
+0.36%-1.80%+23.42%+10.93% 3.9TCr
-0.50%+0.85%+20.60%+58.18% 3.26TCr
+0.25%-2.42% - - 1.63TCr
+1.02%-2.94%+26.32%+130.58% 1.61TCr
-0.62%-0.06%+3.95%+27.74% 1.42TCr
+2.39%+3.51%+82.65%+43.46% 1.34TCr
Average +0.96%-0.49%+64.55%+101.24% 2.63TCr
Weighted average by Cap. +1.45%-0.63%+99.75%+149.16%

Financials

2024 2025
Net sales 11Cr 33.44L 28.88L 27.14L 24.68L 46.41L 32Cr 47.17L 3.18Cr 1.24Cr 16Cr 1.26Cr 1.23Cr 53Cr 4.06Cr 12.69L 10.96L 10.3L 9L 17.61L 12Cr 17.9L 1.21Cr 47.18L 6.08Cr 47.64L 46.61L 20Cr
Net income -250.26Cr -7.82Cr -6.76Cr -6.35Cr -5.77Cr -11Cr -747.93Cr -11Cr -74Cr -29Cr -374.54Cr -29Cr -29Cr -1.24TCr -392.71Cr -12Cr -11Cr -9.96Cr -9.06Cr -17Cr -1.17TCr -17Cr -116.72Cr -46Cr -587.73Cr -46Cr -45Cr -1.95TCr
Net Debt 91.92L 3L 2L 2L 2L 4L 2.75Cr 4L 27.32L 10.68L 1.38Cr 10.79L 10.55L 4.57Cr 52Cr 1.62Cr 1.4Cr 1.31Cr 1.19Cr 2.24Cr 154.48Cr 2.28Cr 15Cr 6.01Cr 77Cr 6.07Cr 5.93Cr 257.07Cr
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
17/26/17 NT$10.80 -1.37% 8,13,283
14/26/14 NT$10.95 -1.35% 4,35,515
13/26/13 NT$11.10 +1.37% 9,32,924
12/26/12 NT$10.95 -0.45% 6,34,528
11/26/11 NT$11.00 -2.22% 8,11,642
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock